Clinical Trials Logo

Clinical Trial Summary

Currently in Canada, and at the Cross Cancer Institute, the treatment of many women with breast cancer involves radiotherapy (RT). There is a complex process which takes place in order to plan the radiation therapy before patients commence their treatment. In many circumstances the investigators use computerized technology to assist in planning their treatment. This allows more precision in delivering the treatment to the desired areas and avoiding areas of normal tissue.

Once the planning process is completed, the investigators then place marks with a marker pen on the skin of the patient to outline the area where the radiation will be delivered. The investigators confirm that the correct area is being treated with an x-ray taken on the treatment unit while the patient is in the treatment position. This is called a port film or verification film. The investigators then compare this to what they set up with the computerized data. If all the information matches, the patient is then treated for the full course of radiation, with the assumption that all treatments are given in the correct position. No further routine checking is done.

The standard at some radiotherapy centers is that the patient treatment position is verified weekly by a portal film. At the Cross Cancer Institute the investigators normally only do it once at the beginning of treatment.

No information is available to confirm the necessity of doing more frequent verification films, but in view of the very complex nature of the investigators' treatment delivery, it may be necessary to confirm the accuracy of their treatment more often.

Over the course of a 4-5 week treatment the investigators know that some patients may lose weight, some become more relaxed after a few days, and some have trouble with the movement in their shoulders; all of these factors influence the positioning of the patient. Measurements taken on the treatment unit often change during the course of a patient's treatment, but no further verification is performed to ensure that the treated area is still what was initially intended. It is important from a quality assurance standpoint to see if more frequent checking of the radiation treatment set-up is indicated.


Clinical Trial Description

OBJECTIVES:

Primary:

To determine if the verification film (port film) taken and accepted as correct at the beginning of a course of radiotherapy is adequate to ensure accurate position of treatment delivery for a 4-5 week course of radiotherapy in breast cancer patients.

Secondary:

- To assess the feasibility of doing on line portal imaging for breast cancer radiotherapy treatment.

- To possibly identify a patient population that should be verified daily with on line portal imaging.

DISCUSSION:

Quality assurance is a very important aspect of radiotherapy delivery. There are many facets of quality assurance but a basic concept is to ensure the radiation is delivered to the correct target area. At the start of a course of radiotherapy treatment the standard at the Cross Cancer Institute is to confirm the correct area is being treated. This is done by taking an x-ray on the treatment unit with the patient in the treatment position (portal image or verification film). This portal image is examined by the treating oncologist and compared to the simulation film or a digitally reconstructed radiograph that was generated when the patient was simulated (set up) for radiotherapy treatment. Some alterations may be suggested by the oncologist but once a portal film is deemed to reflect the original set-up - no more routine verifications are performed. It is assumed that the treatment set-up will be accurate for the remainder or the treatments.

Numerous changes may occur when a patient undergoes a 4-5 week course of RT. The patient may relax after a few treatments, a patient can lose weight, surgical changes can settle, all altering the original set up.

There are no data to determine how often a set up should be verified. Ideally it should be checked daily prior to each treatment initiation. This can be done with on line portal imaging however resources currently do not allow on line portal imaging for every patient. By evaluating the impact of weekly portal images the investigators may be able to identify a population of patients that would benefit from more frequent portal images or patients who would benefit from daily on line portal images, allowing for appropriate resource allocation.

Currently in Canada, and at the Cross Cancer Institute, the treatment of many women with breast cancer involves radiotherapy. There is a complex process which takes place in order to plan the radiation therapy before patients commence their treatment. In many circumstances the investigators use computerized technology to assist in planning their treatment. This allows more precision in delivering the treatment to the desired areas and avoiding areas of normal tissue.

Once the planning process is completed, the investigators then place marks with a marker pen on the skin of the patient to outline the area where the radiation will be delivered. The investigators confirm that the correct area is being treated with an x-ray taken on the treatment unit while in the treatment position. This is called a port film or verification film. The investigators then compare this to what they set up with the computerized data. If all the information matches, the patient is then treated for the full course of radiation, with the assumption that all treatments are given in the correct position. No further checking is done.

The standard at some radiotherapy centers is that the patient treatment position is verified weekly by a portal film. At the Cross Cancer Institute the investigators only do it once at the beginning of treatment.

No information is available to confirm the necessity of doing more frequent verification films, but in view of the very complex nature of the investigators' treatment delivery, it may be necessary to confirm the accuracy of their treatment more often.

Over the course of a 4-5 week treatment the investigators know that some patients may lose weight, some become more relaxed after a few days, and some have trouble with the range of movement in their shoulders; all of these factors influence the positioning of the patient. Measurements taken on the treatment unit often change during the course of a patients treatment, but no further verification is performed to ensure that the treated area is still what was initially intended.

STUDY DESIGN:

This is a single institute pilot project.

PATIENT CRITERIA/SAMPLE SIZE:

Any breast cancer patients receiving a course of radiotherapy to treat the breast, chest wall and/or regional lymph nodes.

One-hundred consecutive consenting patients will be analyzed prospectively. Patients will be stratified as per treatment area: breast only, breast plus regional nodes, chest wall only and chest wall plus regional nodes. The treatment technique will also be evaluated.

METHODOLOGY:

Patients eligible and consenting will be sequentially selected to undergo the standard radiotherapy planning process and initial verification films. In addition to the standard initial verification films, all patients will have additional verification films taken weekly. These will be reviewed by the treating radiation oncologist and a data form will be completed. The treatment record will also be examined and any changes noted by the therapists during the course of radiotherapy will be recorded.

No additional amount of radiation is given to the patient. The amount of radiation required to take the verification films is subtracted from the amount of radiation delivered at the time of treatment.

The data will be compiled and compared to establish any relationship between target volume (breast only, breast plus regional nodes, chest wall only and chest wall plus regional nodes) or technique used to the acceptability rate and accuracy of the verification films. ;


Study Design

N/A


Related Conditions & MeSH terms


NCT number NCT00123812
Study type Observational
Source AHS Cancer Control Alberta
Contact
Status Withdrawn
Phase N/A
Start date March 2004
Completion date July 2006

See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2